B. Doger de Spéville

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer

George R. Blumenschein, Siddhartha Devarakonda, Melissa L. Johnson et al. · Journal for ImmunoTherapy of Cancer · 2022 · 48 citations · Full text

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

B. Doger de Spéville, Enriqueta Felip, Martin Förster et al. · Journal of Clinical Oncology · 2023 · 13 citations · Full text

Immunology, Immunoediting, Pathology +20

Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors

Elena Garralda, V. Moreno, G. Alonso et al. · European Journal of Cancer · 2022 · 10 citations · Full text

Class Pan-myc-inhibitor, Medicine, Pharmacology +8

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

M. Majem, M.D. Forster, M.G. Krebs et al. · Journal of Thoracic Oncology · 2023 · 10 citations · Full text

Final Data, Oncology, Medicine +8

1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

Antonio Calles, A.F. Navarro Mendivil, B. Doger de Spéville et al. · Annals of Oncology · 2023 · 10 citations · Full text